ClinicalTrials.gg
CompletedNCT03620981Updated Nov 14, 2024Results posted

Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type

A Phase 2/3 interventional study of Brexpiprazole and Placebo in Agitation Associated With Dementia of the Alzheimer's Type, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 55 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-11-14.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
410
Allocation
Randomized
Ages
55 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Dementia by Otsuka Holdings Co., Ltd. — none open to participants now, none under way, none of them phase 3. Dementia · Otsuka Holdings Co., Ltd..

Enrollment
4th of 10
410 · median 377
Started
2018
with 1 other
Phase 2/3
Only one
of the 11
Registered
10th of 11
by date

Among the 11 studies in Dementia by Otsuka Holdings Co., Ltd., this one is the 4th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2018, is the only one in phase 2/3, and was the 10th registered.

Dementia

2,375 studies on the registry are indexed under Dementia; 574 are open to participants now.

Browse Dementia studies →

Open to participants now

None of the 11 studies in Dementia by Otsuka Holdings Co., Ltd. is open now. The open studies under Dementia, anywhere →

Who these studies take

Of the 383 Dementia studies recruiting now, 244 (64%) set no upper age limit and 25 (7%) stop at 75 or younger; 16 take children under 18; 164 take healthy volunteers.

This study: 55 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Dementia by Otsuka Holdings Co., Ltd. as a file.
02

Study summary

To evaluate the superiority of brexpiprazole 1 mg or 2 mg over placebo after a 10-week treatment regimen for agitation associated with dementia of the Alzheimer's type in patients who require medication, and to investigate the safety of brexpiprazole and identify the optimum dose.

03

Conditions studied

  • Agitation Associated With Dementia of the Alzheimer's Type

Browse trials for

04

Who can participate

Ages eligible
55 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who satisfy both of the following diagnostic criteria:

    1. Diagnosis of "Dementia due to Alzheimer's Disease" according to .
    2. Diagnosis of "Probable Alzheimer's Disease" according to NINCDS-ADRDA.
  • Hospitalized patients or care facility patients or care at home patients
  • Patients with an score of 1 to 22
  • Patients who have the agitation defined according to the "Consensus provisional definition of agitation in cognitive disorders" from the International Psychogeriatric Association (IPA)

Exclusion criteria

Exclusion Criteria:

  • Patients who have dementia other than dementia of the Alzheimer's type
  • Patients diagnosed with delirium between 30 days before the screening examination and baseline evaluation according to .
  • Patients diagnosed with any of the following disorders according to DSM-5:

    • Schizophrenia spectrum and other psychotic disorders
    • Bipolar and related disorders
    • Major depressive disorder
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
410 participants (actual)

Study arms

  • Experimental
    Brexpiprazole, 1mg/day

    Drug: 1mg/day Once daily for 10 weeks

    Drug: Brexpiprazole

  • Experimental
    Brexpiprazole, 2mg/day

    Drug: 2mg/day Once daily for 10 weeks

    Drug: Brexpiprazole

  • Placebo comparator
    Placebo

    Drug: Placebo (0mg/day) Once daily for 10 weeks

    Drug: Placebo

Interventions

  • Drug: 1 tablet /day Once daily for 10 weeks

  • DrugPlacebo

    Placebo: 1 tablet /day Once daily for 10 weeks

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Cohen-Manfield Agitation Inventory(CMAI) Score at 10 Weeks After Dosing.

    The CMAI assessed the frequency of agitated behaviors in elderly persons, such as hitting, cursing, and restlessness. It consisted of 29 items all rated on a 1 to 7 scale with 1 being the "best" rating and 7 being the "worst" rating. The minimum possible CMAI total score was 29, and the maximum possible CMAI total score was 203. A decrease in score indicated improvement in symptoms.

    Time frame: Baseline and 10 weeks first dose, on average 10 weeks

Secondary outcomes

  1. Change From Baseline in Clinical Global Impression of Severity (CGI-S) Score at 10 Weeks After Dosing.

    The CGI-S was used to rate the severity of agitation. Scores were: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants. A decrease in score indicated improvement in symptoms.

    Time frame: Baseline and 10 weeks first dose, on average 10 weeks

  2. Clinical Global Impression of Improvement (CGI-I) Score at 10 Weeks After Dosing.

    The CGI-I Scale was clinician-rated scale which assessed the total improvement of the patient's condition compared to that at baseline. Scores range from 0 to 7: 0 = Not assessed, 1= Very much improved, 2 = Much improved, 3= Minimally improved, 4= No change, 5= Minimally worse, 6= Much worse, 7= Very much worse. Higher scores indicate worse condition.

    Time frame: Baseline and 10 weeks first dose, on average 10 weeks

07

Results

Posted Nov 14, 2024

Participant flow

Participant flow — Overall Study
MilestoneBrexpiprazole 1 mgBrexpiprazole 2 mgPlacebo
Started112149149
Completed83102116
Not completed294733
Withdrew: Adverse event143825
Withdrew: Lack of efficacy211
Withdrew: Physician decision744
Withdrew: Protocol violation121
Withdrew: Withdrawal by legal representative211
Withdrew: Withdrawal by care giver201
Withdrew: Non-compliance with study drug110

Outcome measures

PrimaryChange From Baseline in Cohen-Manfield Agitation Inventory(CMAI) Score at 10 Weeks After Dosing.

The CMAI assessed the frequency of agitated behaviors in elderly persons, such as hitting, cursing, and restlessness. It consisted of 29 items all rated on a 1 to 7 scale with 1 being the "best" rating and 7 being the "worst" rating. The minimum possible CMAI total score was 29, and the maximum possible CMAI total score was 203. A decrease in score indicated improvement in symptoms.

Time frame:
Baseline and 10 weeks first dose, on average 10 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline in Cohen-Manfield Agitation Inventory(CMAI) Score at 10 Weeks After Dosing.
units on a scaleBrexpiprazole 1 mgBrexpiprazole 2 mgPlacebo
Change From Baseline in Cohen-Manfield Agitation Inventory(CMAI) Score at 10 Weeks After Dosing.-11.7 ± 1.20-15.2 ± 1.05-8.0 ± 1.03
Statistical analysis
  • Brexpiprazole 2 mg vs Placebo · Mixed Models Analysis · p = < 0.0001 · Ls mean difference (final values): -7.2 · 95% CI -10.0 to -4.3
  • Brexpiprazole 1 mg vs Placebo · Mixed Models Analysis · p = 0.0175 · Ls mean difference (final values): -3.7 · 95% CI -6.8 to -0.7
SecondaryChange From Baseline in Clinical Global Impression of Severity (CGI-S) Score at 10 Weeks After Dosing.

The CGI-S was used to rate the severity of agitation. Scores were: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants. A decrease in score indicated improvement in symptoms.

Time frame:
Baseline and 10 weeks first dose, on average 10 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline in Clinical Global Impression of Severity (CGI-S) Score at 10 Weeks After Dosing.
units on a scaleBrexpiprazole 1 mgBrexpiprazole 2 mgPlacebo
Change From Baseline in Clinical Global Impression of Severity (CGI-S) Score at 10 Weeks After Dosing.-1.0 ± 0.1-1.4 ± 0.09-0.6 ± 0.09
Statistical analysis
  • Brexpiprazole 2 mg vs Placebo · Mixed Models Analysis · p = < 0.0001 · Ls mean difference (final values): -0.8 · 95% CI -1.0 to -0.5
  • Brexpiprazole 1 mg vs Placebo · Mixed Models Analysis · p = 0.0083 · Ls mean difference (final values): -0.3 · 95% CI -0.6 to -0.1
SecondaryClinical Global Impression of Improvement (CGI-I) Score at 10 Weeks After Dosing.

The CGI-I Scale was clinician-rated scale which assessed the total improvement of the patient's condition compared to that at baseline. Scores range from 0 to 7: 0 = Not assessed, 1= Very much improved, 2 = Much improved, 3= Minimally improved, 4= No change, 5= Minimally worse, 6= Much worse, 7= Very much worse. Higher scores indicate worse condition.

Time frame:
Baseline and 10 weeks first dose, on average 10 weeks
Reported as:
Mean · units on a scale
Clinical Global Impression of Improvement (CGI-I) Score at 10 Weeks After Dosing.
units on a scaleBrexpiprazole 1 mgBrexpiprazole 2 mgPlacebo
Clinical Global Impression of Improvement (CGI-I) Score at 10 Weeks After Dosing.3.1 ± 1.32.6 ± 1.23.5 ± 1.4
Statistical analysis
  • Brexpiprazole 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = < 0.0001 · Mean difference (final values): -0.9 · 95% CI -1.2 to -0.6Cochran Mantel Haenszel (CMH), Last observation carried forward (LOCF)
  • Brexpiprazole 1 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0052 · Mean difference (final values): -0.5 · 95% CI -0.8 to -0.1CMH, LOCF

Adverse events

Collected over Adverse events were monitored from signing of the informed consent form until follow-up for up to 35 days after the final day of IMP administration, on average 19 weeks. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brexpiprazole 1 mg2/112 (1.8%)7/112 (6.3%)77/112 (68.8%)
Brexpiprazole 2 mg0/149 (0%)9/149 (6%)113/149 (75.8%)
Placebo0/149 (0%)7/149 (4.7%)93/149 (62.4%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventBrexpiprazole 1 mgBrexpiprazole 2 mgPlacebo
Pneumonia aspirationInfections and infestations2/1122/1490/149
AgitationPsychiatric disorders1/1120/1492/149
Cardiac deathGeneral disorders1/1120/1490/149
Hepatic massHepatobiliary disorders1/1120/1490/149
Femoral neck fractureInjury, poisoning and procedural complications1/1121/1490/149
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1121/1490/149
IIIrd nerve paralysisNervous system disorders1/1120/1490/149
AnaemiaBlood and lymphatic system disorders0/1121/1490/149
PneumoniaInfections and infestations0/1120/1491/149
Femur fractureInjury, poisoning and procedural complications0/1120/1491/149
Most frequent other events
Showing 10 of 57
Most frequent other events
EventBrexpiprazole 1 mgBrexpiprazole 2 mgPlacebo
SomnolenceNervous system disorders9/11224/1493/149
InsomniaPsychiatric disorders16/11218/14922/149
BradykinesiaNervous system disorders8/11220/1490/149
ContusionInjury, poisoning and procedural complications9/1129/14919/149
Salivary hypersecretionGastrointestinal disorders1/11218/1491/149
Muscle rigidityMusculoskeletal and connective tissue disorders9/11216/1491/149
AgitationPsychiatric disorders2/1124/14916/149
Gait disturbanceGeneral disorders5/11215/1491/149
FallInjury, poisoning and procedural complications9/11214/1499/149
PyrexiaGeneral disorders9/11211/1498/149

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Brexpiprazole 1 mgBrexpiprazole 2 mgPlaceboTotal
<=18 years0000
Between 18 and 65 years74415
>=65 years105145145395
Age, Continuous
Age, Continuous(years)Brexpiprazole 1 mgBrexpiprazole 2 mgPlaceboTotal
Mean79.3 ± 7.480.2 ± 6.480.3 ± 6.780.0 ± 6.8
Sex: Female, Male
Sex: Female, Male(Participants)Brexpiprazole 1 mgBrexpiprazole 2 mgPlaceboTotal
Female7110587263
Male414462147
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Brexpiprazole 1 mgBrexpiprazole 2 mgPlaceboTotal
American Indian or Alaska Native0000
Asian112149149410
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Brexpiprazole 1 mgBrexpiprazole 2 mgPlaceboTotal
Japan112149149410
08

Study locations

1 site
  • Jisenkai Nanko Psychiatric Institute
    Shirakawa, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal.

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article Publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2018 to primary completion in Apr 2023, 56 months.

Results were first posted in Nov 2024, 1 year 6 months after primary completion.

Of 20 phase 2/3 interventional studies under Dementia, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 59. This study's 56 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2018
First posted
Aug 8, 2018
StartActual
Aug 20, 2018
Primary completionActual
Apr 21, 2023
CompletionActual
May 15, 2023
Results first posted
Nov 14, 2024
Last update
Nov 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03620981
Responsible party
Sponsor
First posted
Aug 8, 2018
Start date
Aug 20, 2018
Primary completion
Apr 21, 2023
Completion
May 15, 2023
Results posted
Nov 14, 2024
Last update
Nov 14, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexpiprazole

Start the discussion